Search
Search Results
##search.searchResults.foundPlural##
-
-
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1253PDF: 984HTML: 110 -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries
1207PDF: 820HTML: 261 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1388PDF: 1018HTML: 207 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2096PDF: 1939HTML: 144 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
946PDF: 954Suppl. Files: 617HTML: 99 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
1950PDF: 1381HTML: 247 -
DISSEMINATED HISTOPLASMOSIS AS AIDS PRESENTATION. CASE REPORT AND COMPREHENSIVE REVIEW OF CURRENT LITERATURE
3586PDF: 1255HTML: 705Figure 2: 432Figure 1: 3095 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
3802PDF: 1434HTML: 8488 -
FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia
551PDF: 192Html: 25 -
ASSESSMENT OF THE EFFICACY OF PROCALCITONIN, C-REACTIVE PROTEIN AND ALBUMIN LEVELS-GUIDED ANTIBIOTICS USE IN SEPSIS
868PDF: 455Html: 129Suppl. Files: 159 -
APPROPRIATE DURATION OF INTRAVENOUS TREATMENT OF CANDIDEMIA AND TIMING OF STEP DOWN TO ORAL THERAPY IN NON-NEUTROPENIC PATIENTS
2719PDF: 929HTML: 344Preferred Reviewers: 195 -
RELIABILITY OF DIFFERENT RBC INDICES AND FORMULAS IN DISCRIMINATING BETWEEN ?-THALASSEMIA MINOR AND OTHER CAUSES OF MICROCYTIC HYPOCHROMIC ANEMIA
1932PDF: 1600HTML: 14611Untitled: 193Untitled: 160 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
806PDF: 962Suppl. Files: 124HTML: 62 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2106PDF: 1747HTML: 124 -
-
-
-
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,
3591PDF: 1387HTML: 170 -
AN INEXPENSIVE CLINICAL-LABORATORY NOMOGRAM TO PREDICT POST-TREATMENT LUNG DESTRUCTION IN PULMONARY TUBERCULOSIS
474PDF: 199Suppl. Files: 52Html: 34 -
THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES Gene therapy for Hemoglobinopathies.
2015PDF: 1181Html: 261 -
CD56+/CD38+ Neutrophils: Rapid and Specific Flow Cytometric Signature for Chronic Myeloid Leukemia
30PDF: 43Suppl. Files: 7HTML: 3 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3451PDF: 1138HTML: 4976Incidence age-standardized rates for HL across the Mediterranean basin: 179







